MODULATION OF NITRIC OXIDE SYNTHASES BY BETAINES
First Claim
1. A method for treating a patient suffering of at least one trouble related to constitutive nitric oxide deficiency, comprising the step of administering to in which the patient is administered with an efficient therapeutical amount of betaine for increasing in said patient at least one nitric oxide production pathway selected from the group consisting of constitutive nitric oxide synthase expression, constitutive Endothelial nitric oxide synthase expression, eNOS nitric oxide synthase expression, neural NOS nitric oxide synthase expression (nNOS), platelet NOS nitric oxide synthase expression, cNOS nitric oxide synthase expression, Type III nitric oxide synthase expressions, calcium dependant nitric oxide synthase expression, calcium dependant nitric oxide synthase production, endogenous nitric oxide production, and combinations thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.
-
Citations
64 Claims
- 1. A method for treating a patient suffering of at least one trouble related to constitutive nitric oxide deficiency, comprising the step of administering to in which the patient is administered with an efficient therapeutical amount of betaine for increasing in said patient at least one nitric oxide production pathway selected from the group consisting of constitutive nitric oxide synthase expression, constitutive Endothelial nitric oxide synthase expression, eNOS nitric oxide synthase expression, neural NOS nitric oxide synthase expression (nNOS), platelet NOS nitric oxide synthase expression, cNOS nitric oxide synthase expression, Type III nitric oxide synthase expressions, calcium dependant nitric oxide synthase expression, calcium dependant nitric oxide synthase production, endogenous nitric oxide production, and combinations thereof.
- 17. A method for treating a patient suffering at least one trouble related to Tissue Factor Pathway Inhibitor (TFPI) deficiency, in which the patient is administered with an efficient therapeutical amount of betaine for increasing Tissue Factor Pathway Inhibitor (TFPI) in said patient.
- 23. A method for treating a patient suffering at least one trouble related to excess of endothelin-1 (ET-1), in which the patient is administered with an efficient therapeutical amount of betaine for lowering endothelin-1 (ET-1) levels in said patient.
- 26. A method for treating a patient suffering of at least one trouble selected from the group consisting of troubles related to cyclic guanosine monophosphate (cGMP) deficiency, troubles related to cyclic guanosine monophosphate (cGMP) depletion, troubles related to rapid depletion of cyclic guanosine monophosphate, troubles related to rapid metabolizing of cyclic guanosine monophosphate, troubles related to rapid degradation of cyclic guanosine monophosphate, and combinations thereof, in which the patient is administered with an efficient therapeutical amount of betaine for increasing in said patient at least one parameter selected from the group consisting of cyclic guanosine monophosphate (cGMP) expression, cyclic guanosine monophosphate (cGMP) production, cyclic guanosine monophosphate (cGMP) half-life, cyclic guanosine monophosphate (cGMP) stability, and combinations thereof.
- 30. A composition suitable for treating at least one trouble related to nitric oxide deficiency, said composition comprising (a) L-arginine or a physiologically acceptable salt thereof in a therapeutically effective amount sufficient to enhance nitric oxide production and (b) at least one betaine in a therapeutically effective amount that enhances production of nitric oxide or that inhibits degradation of nitric oxide, the betaine content being advantageously greater than 20% by weight.
- 33. A method for treating a patient suffering at least one trouble related to Tissue Factor Pathway Inhibitor (TFPI) deficiency and at least one trouble related to a nitric oxide deficiency, in which the patient is administered with an efficient therapeutical amount of betaine for increasing in said patient at least one nitric oxide production pathway selected from the group consisting of constitutive nitric oxide synthase expression, constitutive Endothelial nitric oxide synthase expression, eNOS nitric oxide synthase expression, neural NOS nitric oxide synthase expression (nNOS), platelet NOS nitric oxide synthase expression, cNOS nitric oxide synthase expression, Type III nitric oxide synthase expressions, calcium dependant nitric oxide synthase expression, calcium dependant nitric oxide synthase production, endogenous nitric oxide production, and combinations thereof, said amount of betaine being furthermore therapeutically efficient for increasing Tissue Factor Pathway Inhibitor (TFPI) in said patient.
-
39. A method for treating a patient suffering at least one trouble related endothelial cells, in which said patient is administered an efficient therapeutical amount of betaine for improving endothelial cell function through activation of eNOS and through protection of the endothelium from oxidative stress.
-
40. A method for treating a patient suffering at least one trouble related to lack of activated eNOS, in which said patient is administered an efficient therapeutical amount of betaine to destabilize the complex between eNOS and caveolin for activating eNOS.
-
44. A method for increasing constitutive Nitric Oxide Synthase activity in a subject to treat a condition favorably affected by an increase in constitutive Nitric Oxide levels in a cell, a tissue, an organ, a bodily fluid, blood, comprising:
- administering to a subject in need of such treatment an effective amount of a betaine.
- View Dependent Claims (45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)
-
62. A method for treating a patient suffering at least one trouble selected from the group consisting of troubles related to free radicals, troubles related to superoxide anion and troubles related to the lack of normal vaso-relaxation, in which said patient is administered an efficient amount of betaine for reducing in plasma the level of free radicals and/or for diminishing superoxide anion generation and/or for improving the endothelium-dependent vaso-relaxation.
-
63. A method for treating a patient at risk of brain injury resulting from a stroke or at risk of ischemic stroke, said method comprising:
- administering to said patient betaine in an amount effective to increase constitutive Nitric Oxide Synthase activity in the brain tissue of the subject.
-
64. A method for treating a patient suffering at least one trouble selected from troubles related to TFPI activity deficiency and at least one trouble related to NO deficiency, in which the patient is administered an efficient therapeutic amount of betaine for increasing the activity of TFPI and for increasing the NO blood content or the NO activity in said patient.
Specification